Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes
- Author(s)
- Wei, AH; Seymour, JF;
- Details
- Publication Year 2022-08,Volume 198,Issue #3,Page 415-418
- Journal Title
- British Journal of Haematology
- Publication Type
- Commentary
- Abstract
- Hypomethylating agents remain the current standard of care for patients with higher-risk myelodysplastic syndromes. Ades et al. report outcomes from a randomised 'pick-a-winner' study design that examined the addition of either lenalidomide, valproic acid or idarubicin in combination with azacitidine, compared to azacitidine alone. Commentary on: Ades et al. A randomised phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS: GFM's 'pick a winner' trial, with the impact of somatic mutations. Br J Haematol 2022;198:535-544.
- Keywords
- Azacitidine/therapeutic use; Clinical Trials, Phase II as Topic; Humans; Idarubicin; Lenalidomide/therapeutic use; *Myelodysplastic Syndromes/drug therapy/genetics; Randomized Controlled Trials as Topic; Valproic Acid/therapeutic use; Hypomethylating agents; lenalidomide; myelodysplastic syndromes
- Department(s)
- Haematology
- PubMed ID
- 35544384
- Publisher's Version
- https://doi.org/10.1111/bjh.18240
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-05-09 06:08:23
Last Modified: 2025-05-09 06:09:24